New York, NY ; 03/25/2020
Amount Funded: $112 Million
Type: Series C
Participating Investor(s): The Column Group, Lux Capital, Polaris Partners, Two Sigma Ventures, Eculidean Capital, Illumina Ventures, Alexandria Venture Investments, Casdin Captial, Greenspring Associates, Bill Gates, additional unnamed investors
Company Description: Kallyope, headquartered at the Alexandria Center for Life Science in New York City, is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company’s cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D.
What funding will be used for: Advance its line of programs, clinical trials.
“Four years ago, we started our journey to build a preeminent biotech based in New York City as a first-mover in the gut-brain axis space. Now, this Series C financing will enable us to advance multiple programs to clinical development.”
-Nancy Thornberry, CEO, Kallyope
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.